Protagenic Therapeutics, Inc.new (PTIX) stock
PTIXOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026
$0.75+0.00 (0.00%)
Close on Oct 19, 2026Market cap $1.36MP/E –Yield –
Protagenic Therapeutics, Inc.new cash
Cash and short-term investments held at the end of each period.
Protagenic Therapeutics, Inc.new's cash was $565.99K at Jun 30, 2026. For fiscal 2024 it was $79.57K, down 98.0% from the year before. Over ten years it grew -19.7% a year on average. The highest annual figure on record is $10.37M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $79.57K | -98.0% |
| FY2023 | Dec 31, 2023 | $4.06M | -49.2% |
| FY2022 | Dec 31, 2022 | $7.98M | -23.1% |
| FY2021 | Dec 31, 2021 | $10.37M | +1445.4% |
| FY2020 | Dec 31, 2020 | $671.09K | -16.0% |
| FY2019 | Dec 31, 2019 | $798.62K | +120.3% |
| FY2018 | Dec 31, 2018 | $362.49K | -9.3% |
| FY2017 | Dec 31, 2017 | $399.69K | -87.1% |
| FY2016 | Dec 31, 2016 | $3.10M | +2969.7% |
| FY2014 | Jun 30, 2014 | $101.00K | -85.9% |
| FY2013 | Jun 30, 2013 | $717.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ1 2026 | Jun 30, 2026 | $565.99K | -64.5% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $79.57K | -98.0% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $71.40K | -98.6% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $713.63K | -88.2% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $1.59M | -79.2% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $4.06M | -49.2% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $5.27M | -35.3% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $6.04M | -31.9% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $7.65M | -21.8% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $7.98M | -23.1% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $8.15M | -24.9% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $8.87M | -25.7% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $9.79M | +5005.2% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $10.37M | +1445.4% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $10.85M | +998.0% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $11.93M | +910.2% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $191.67K | -74.6% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $671.09K | -16.0% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $988.57K | +256.4% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $1.18M | +247.9% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $753.97K | +79.8% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $798.62K | +120.3% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $277.39K | -35.8% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $339.54K | +43.9% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $419.33K | +22.2% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $362.49K | -9.3% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $431.93K | -54.6% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $236.01K | -62.4% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $343.29K | -87.5% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $399.69K | -87.1% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $952.13K | -72.7% |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $627.83K | -83.4% |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $2.74M | -26.8% |
| Q4 FY2016CQ4 2016 | Dec 31, 2016 | $3.10M | +2969.7% |
| Q3 FY2016CQ3 2016 | Sep 30, 2016 | $3.49M | +1755.8% |
| Q2 FY2016CQ2 2016 | Jun 30, 2016 | $3.79M | +2836.6% |
| Q1 FY2016CQ1 2016 | Mar 31, 2016 | $3.75M | – |
| Q4 FY2014CQ2 2014 | Jun 30, 2014 | $101.00K | – |
| Q3 FY2014CQ1 2014 | Mar 31, 2014 | $188.00K | – |
| Q2 FY2014CQ4 2013 | Dec 31, 2013 | $129.00K | – |
See a number that looks wrong?